Global Oncology Academy

Study Shows Importance of Comprehensive Genomic Profiling for NSCLC

ReachMD Healthcare Image

What do we need to know about comprehensive genomic profiling and CGP-directed therapies for NSCLC patients?

  • Overview

    This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free